– CANADA, Laval – Thryv Therapeutics Inc. today announced the appointment of Dr. Shi Yin Foo to its Board of Directors, bringing an impressive depth of development and company-building expertise to the Board.
“The addition of Dr. Foo will be critical as our portfolio transitions into clinical studies for the treatment of long QT syndromes and other arrhythmias. Her insights will be instrumental in helping us to build a world-class organization intended to bring much-needed therapies to those in need,” said Chairman and CEO, Paul Truex.
About Dr. Shi Yin Foo
Dr. Shi Yin Foo brings over 20 years of experience as a practicing physician and a catalyst in advancing innovative new programs through the various stages of drug development. She has translational expertise in a breadth of disease areas, including cardiorenal, immunology/inflammation, and rare diseases, as well as an interest in novel and adaptive clinical trial designs. Dr. Foo has been in multiple executive roles, including at Cardioxyl Pharmaceuticals, Cydan Therapeutics, Imara Therapeutics, and Tiburio Therapeutics, where she was also an Observer on the Board. Dr. Foo is the scientific founder and CEO of Arvada Therapeutics, a company working on novel therapeutics for rare arrhythmic diseases.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
